603 SUPRAME: a phase 3 trial evaluating IMA203 PRAME-directed TCR T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma
Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A687-A687
10.1136/jitc-2025-sitc2025.0603